Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perifosine in Advanced Pancreatic Carcinoma
NCT00053924Phase 2Completed
- Sponsor
- University Health Network
- Start
- May 2003
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perifosine in pancreatic adenocarcinoma (PDAC), sponsored by University Health Network. Primary endpoint: 6-month survival rate. Started May 2003; status: completed.
02
Drugs
perifosine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00053924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053924.